Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$1.77MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert Goodman
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 54
- Beta
- 0.15
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -16.42
Financials
Revenue
$1.77M-77.1%Net Income
$-7.93MEBITDA
$-6.46MFree Cash Flow
$-5.15MEPS (diluted)
$-11.00Shares Outstanding (diluted)
721.3K+398.1%Operating Expenses
$6.84MCash & Debt
$9.81MReturn of Capital
$0.00Revenue by Segment (annual)
$7.68MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $7.68M | $-33.25M | $-4.01 |
| 2025 | $3.71M | $-46.63M | $-275.40 |
| 2024 | $1.16M | $-60.24M | $-726.60 |
| 2023 | $0.00 | $-55.82M | $-744.80 |
| 2022 | $0.00 | $-43.18M | $-672.80 |
| 2021 | $873.0K | $-22.88M | $-508.20 |
| 2020 | $1.39M | $-19.94M | $-711.40 |
| 2019 | $7.72M | $-6.56M | $-308.69 |
| 2018 | $0.00 | $-18.04M | $-1204.00 |
| 2017 | $0.00 | $-3.72M | $-25.70 |
| 2016 | $0.00 | $-29.7K | $-0.21 |
| 2015 | $0.00 | $-4.81M | $-33.20 |
| 2014 | $0.00 | $-1.65M | $-11.40 |
Valuation
XAIRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
60-50.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·36d ago·Negative
…ation for LungFit® GO to Treat Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) GARDEN CITY, N.Y., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve patients' lives, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to LungFit GO for the treatment of nontub…
View source ↗ - Newsglobenewswire.com·42d ago·Negative
…igible to receive up to $32.5 million in development and commercial milestone payments GARDEN CITY, N.Y., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) today announced that they have entered into a definitive agreement under which UNIVO Pharmaceutical Industries Ltd (“UNIVO”) Univo Pharmaceutical Industries Ltd.
View source ↗ - Newsseekingalpha.com·53d ago·Positive
Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript Beyond Air, Inc. (XAIR) Q1 2027 Earnings Call Transcript
View source ↗
Earnings
Tue, Nov 10(in 5 weeks)
Consensus estimate $-3.31 per share
Typical surprise -2.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-11.00 vs $-10.80miss
- Fri, Jun 26$-15.40 vs $-11.33miss
- Fri, Feb 13$-17.00 vs $-15.01miss
- Mon, Nov 10$-25.00 vs $-15.47miss
- Tue, Aug 12$-30.60 vs $-30.00miss
- Tue, Jun 17$-36.00 vs $-48.80beat
Estimates and results for XAIR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by XAIR officers and directors.
- Bought
- $984k
- Sold
- —
13 trades
0 trades
- Lin Yi-chienbought
- Lin Yi-chienbought
- Lin Yi-chienbought
- Goodman Robert Scottbought
- Goodman Robert Scottbought
- Goodman Robert Scottbought
- Moorhead Daniel Jbought
- Moorhead Daniel Jbought
87 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in XAIR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.